Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LAB International has reported enrollment of the first patient in the extension arm of its Fentanyl Taifun phase IIb trial for patients with cancer pain.
Subscribe to our email newsletter
Fentanyl Taifun is a fast-acting Fentanyl formulation delivered using its Taifun dry powder inhaler platform. Chronic pain associated with advanced cancer is commonly treated with strong opioid analgesics, such as fentanyl.
The phase IIb trial will evaluate cancer patients with severe persistent pain on maintenance opioid therapy. The first part of the trial will evaluate the effectiveness of each individual dose for significant pain relief with Fentanyl Taifun in the treatment of breakthrough cancer pain. The required enrolment of 32 patients is expected to be completed by the end of this quarter.
The second part will continue with a total of 28 patients from the open label part and is expected to be completed before the end of the second quarter of 2007.
“We are confident that Fentanyl Taifun will continue to demonstrate the same superior therapeutic properties, significant and rapid pain relief previously demonstrated. We strongly believe that Fentanyl Taifun will provide these cancer patients with a superior therapeutic alternative for the treatment of their pain attacks,” said Dr Halvor Jaeger, CEO of LAB International.